Alx Oncology Holdings Inc(ALXO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.14 | Insider Own | 22.98% | Shs Outstand | 138.2M | Perf Week | 2.52% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 2.21% | Insider Trans | -0.01% | Shs Float | 106.5M | Perf Month | -12.23% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.13 | Inst Own | 62.34% | Short Float | 5.61% | Perf Quarter | -37.11% |
| Income | -0.08B | P/S | - | EPS this Y | 70.56% | Inst Trans | 16.36% | Short Ratio | 4.82 | Perf Half Y | -28.24% |
| Sales | 0.00B | P/B | 1.24 | EPS next 5Y | 34.91% | ROA | -63.16% | Short Interest | 5.98M | Perf YTD | 7.96% |
| Book/sh | 0.99 | P/C | 1.22 | EPS past 3/5Y | 14.52% -8.19% | ROE | -80.65% | 52W High | -54.14% ($2.66) | Perf Year | -23.27% |
| Cash/sh | 1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -55.41% | 52W Low | 41.58% ($0.86) | Perf 3Y | -81.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 48.2% | Gross Margin | - | Volatility(W/M) | 13.72% 13.31% | Perf 5Y | -97.82% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.71 | EPS Q/Q | 72.71% | Profit Margin | - | RSI (14) | 47.41 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.71 | Sales Q/Q | - | SMA20 | 6.95% ($1.14) | Beta | 0.6 | Target Price | $4.6 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/8/6 | SMA50 | -20.17% ($1.53) | Rel Volume | 1.23 | Prev Close | $1.18 |
| Employees | 43 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 9.03% - | SMA200 | -33.12% ($1.82) | Avg Volume(3M) | 1.24M | Price | $1.22 |
| IPO | 2020/7/17 | Option/Short | Yes/Yes | Trades | 3445 | Volume | 1,532,613 | Change | 3.39% |
🧬 CD47 is a US clinical-stage biotech company developing immuno-oncology drugs that target immune checkpoints. Its leading candidate, evorpacept, activates macrophage-mediated immunity, and the company is conducting clinical trials across multiple solid tumor indications, including HER2-positive gastric and breast cancers.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded about as much as usual. That is 123% of its average volume.
ALXO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 62.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #317 of 594 in the industry
Based on market cap of $169M.
TRDA#316 Entrada Therapeutics Inc $171M PER - ALXO#317 Alx Oncology Holdings Inc $169M PER - 
IPHA#318 Innate Pharma ADR $168M PER - 
VRXA#319 Veraxa Biotech AG $167M PER 5.3 
PEPG#320 PepGen Inc $167M PER - 
FAQ
What kind of company is ALXO?
ALXO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALXO?
The market cap of ALXO is approximately $169M, ranking 4,154 within its sector.
What is the 52-week high and low for ALXO?
ALXO has recorded a 52-week high of $2.66 and a low of $0.86.
